Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, U.K.
Hyperthyroidism.
Initially 300 to 600mg daily, once daily or in divided doses until the patient becomes euthyroid.
When the condition is controlled (usually after 1-2 months), the dose is reduced to 50 to 150mg daily and continued for 1-2 years.
GFR 10 to 50ml/min, 75% dose
GFR <10ml/min, 50% dose
Reduced dose.
Not recommended.
Initially 50 to 150mg once daily or in divided doses.
Initially 150 to 300mg once daily or in divided doses.
Goitre and hypothyroidism may be induced by repeated over dosage. Single overdose is not dangerous. Overdose may manifest as vomiting, epigastric distress, headache, fever, arthralgia, pruritus, and pancytopenia.
The treatment of propylthiouracil overdose should aim to minimise the amount of drug absorbed into the circulation. Treatment should involve liberal use of oral fluids. Activated charcoal may also be employed. General symptomatic and supportive measures should then be instituted. A full blood analysis should be considered because of the slight risk of haematological complications and appropriate therapy given if bone marrow depression develops.
There is no specific antidote for propylthiouracil.
2 years.
Do not store above 25°C.
Polypropylene or polyethylene container with tamper evident closure of 28, 30, 56, 60, 84, 90 and 100 tablets.
The tablets are administered orally.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
